Thymosin Alpha-1 Side Effects: What Trials Found

Thymosin alpha-1 side effects were usually mild in published human studies. Local discomfort or redness where the injection was given is the clearest recurring reaction. Fatigue and rash appear infrequently, and several larger trials found no meaningful difference from their control groups or no serious drug-related events. That record is useful, but it is not a guarantee: the studies involved different illnesses, sometimes combined drugs with their own effects, and rarely tracked continuous exposure beyond a year.

This page stays with tolerability. Read the thymosin alpha-1 overview for what the peptide is and the separate thymosin alpha-1 dosage guide for how prescribers make dosing decisions.

Thymosin alpha-1 side effects in clinical trials

There is no single reliable percentage for every user. The trials used thymalfasin in people with hepatitis, cancer, sepsis or COVID-19, and adverse-event collection was not uniform. The most defensible answer is to show what each study actually recorded.

The 1996 hepatitis C pilot provides the cleanest description of the recurring local effect: investigators reported only injection-site discomfort in some treated patients. In a 2009 trial, most events considered possibly related to thymalfasin were mild and resolved without sequelae; fatigue appeared twice, but patients were also receiving transarterial chemoembolization (Gish et al., Hepatology International 2009). That is why fatigue belongs on the possible list without being presented as a precise, thymalfasin-only rate.

Rash is rarer still. The international Zadaxin product information groups drug-related adverse events across indications at under 1% and describes primarily local discomfort, with rare erythema and rash. That pooled figure comes from foreign product experience, not a U.S. prescribing label, and should not be treated as a prediction for an individual.

Why the larger safety findings need context

The 2013 ETASS randomized trial reported no serious drug-related event among 361 people with severe sepsis. A later double-blind COVID-19 study recorded 43 mild, 16 moderate and eight serious events among 105 participants, but investigators classified every event as unrelated to the study drug (Shetty et al., Indian Journal of Critical Care Medicine 2022). The eight serious events were deaths in hospitalized patients, not eight reactions attributed to thymosin alpha-1.

The strongest recent check is TESTS. This phase 3 trial analyzed 1,089 adults who received thymosin alpha-1 or placebo for sepsis and found no statistically significant difference in any safety outcome (Wu et al., BMJ 2025). It also found no clear mortality benefit. Together, those results support a narrow conclusion: the short inpatient course did not create a measurable safety imbalance. They do not establish the risk of months or years of use in otherwise healthy adults.

Who needs extra caution

The immune mechanism matters. Foreign Zadaxin product information lists prior hypersensitivity to thymosin alpha-1 or an ingredient as a contraindication. It also says people being deliberately immunosuppressed, including organ-transplant recipients, should generally be considered contraindicated unless the potential benefit outweighs the risk. An immune-modulating drug can work against the purpose of anti-rejection therapy.

Autoimmune disease is a different, less settled question. Immune modulation does not automatically mean an autoimmune flare, but published trials do not provide a dependable flare rate across lupus, rheumatoid arthritis, multiple sclerosis and other distinct diseases. A prescriber needs the exact diagnosis, current activity and full medication list. Our guide to peptides and autoimmune disease explains why one blanket answer is not credible. Pregnancy and breastfeeding data are also too limited to quantify risk.

Widespread hives, facial or throat swelling, breathing difficulty or faintness after an injection are not routine local irritation. Those symptoms warrant urgent medical evaluation. New fever, persistent rash or marked fatigue belongs in a prompt conversation with the prescriber, especially when another immune-active medication is involved.

What long-term safety data cannot answer

Some hepatitis studies followed participants after treatment, but continuous exposure was usually measured in months. A 316-person hepatitis B trial used 24 weeks of treatment followed by observation to week 72; all reported adverse drug reactions were mild, mostly liver-enzyme fluctuations, and incidence was similar between its two study groups (Iino et al., Journal of Viral Hepatitis 2005). That is meaningful follow-up, but it is not multi-year continuous safety surveillance.

There is even less systematic long-term evidence for people using thymosin alpha-1 outside the diseases studied. Absence of a signal in short trials is not proof that rare immune reactions, antibody formation or formulation problems cannot emerge with longer exposure. Immune-support care should therefore be judged by the clinical reason for treatment, the person's history and planned follow-up, not by the phrase “well tolerated” alone.

The product in the vial changes the risk

Thymalfasin, marketed as Zadaxin, has been reported as authorized in more than 35 countries (Goldstein and Goldstein, Expert Opinion on Biological Therapy 2009), but it has not received FDA approval in the United States. The FDA's orphan-drug database confirms designation for chronic hepatitis B but lists the approval status as not approved.

At Promise, thymosin alpha-1 is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. As of August 2026, the FDA's compounding-risk page says compounded thymosin alpha-1 may pose immunogenicity risk for some routes and raises questions about peptide impurities and active-ingredient characterization. Those are formulation and evidence concerns; they are not a measured incidence of symptoms in the trials above.

FDA review status is one input into care, not a marketing gate. A licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision is between the patient and the doctor. A prescription and pharmacy record also create accountability for which formulation was dispensed, something an anonymous vial sold online does not provide.

What the clinical review should catch

A useful review connects the evidence to one person's risk: allergies, an organ transplant, autoimmune history, pregnancy or breastfeeding, active infection, and every prescription or over-the-counter product that affects immune function. At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies. The provider sets the treatment plan and follow-up if a prescription is appropriate.

The bottom line is specific. Brief local reactions are the most consistent finding; fatigue and rash have been reported but are uncommon or difficult to attribute. The larger unknowns are prolonged exposure, immune-sensitive medical histories and whether a compounded formulation matches the identity and quality of the material studied.